Skip to main content
. 2010 May 25;4:493–517. doi: 10.2147/opth.s8980

Table 4.

Summary of characteristics of included studies

Trials Year Country Duration Total subjects (n) Mean age Participants Participants’ VA (Snellen) Interventions Outcomes Trial quality1
Ahmadieh et al20 2007 Iran 24 weeks 115 59.7 ± 8.3 CSME unresponsive to laser <20/40

  1. 1.25 mg IVB

  2. 1.25 mg IVB, 2 mg IVT

  3. control

 BCVA CMT C
Cunningham et al21 2005 USA 36 weeks 172

  1. 61.9

  2. 62.8

  3. 61.3

  4. 64.0

 DME 20/50–20/320

  1. 0.3 mg IVP

  2. 1 mg IVP

  3. 3 mg IVP

  4. control

 BCVA CMT B
Scott et al22 2007 USA 24 weeks 109 65 DME on clinical exam, retinal thickening 20/32–20/320 median 20/50

  1. Laser baseline

  2. 1.25 mg IVB × 2

  3. 2.5 mg IVB × 2

  4. 1.25 mg IVB

  5. 1.25 mg laser week 3

 BCVA CMT C
Soheilian et al23 2007 Iran 12 weeks 103 62.4 ± 6.1 CSME 20/40–20/320

  1. 1.25 mg of IVB

  2. 1.25 mg IVB/4 mg IVT

  3. Laser

 BCVA CMT C
Paccola et al24 2007 Brazil 24 weeks 26

  1. 65.58

  2. 67.08

 Refractory DME despite one session of laser <20/40

  1. IVB 1.5 mg

  2. IVT 4 mg

 BCVA CMT B

Abbreviations: CSME, clinically significant macular edema; DME, diabetic macular edema; BCVA, best-corrected visual acuity; CMT, central macular thickness; IVB, intravitreal bevacizumab; IVP, intravitreal pegaptanib; VA, visual acuity.